Additional case reports of anterior ischemic optic neuropathy (NAION) in semaglutide-treated patients contribute to ongoing safety monitoring of this rare but serious eye event.
Vision loss cases reportedNAION in semaglutide patients — rare but potentially serious, contributing to ongoing FDA/EMA safety evaluation
What the researchers found
Additional NAION cases reported in semaglutide patients, contributing to pharmacovigilance data on this potential safety signal for GLP-1 drugs.
Why it matters
While NAION is rare, it can cause permanent vision loss. With tens of millions taking semaglutide, even a tiny risk increase would affect thousands. Ongoing case documentation helps determine whether the association is real.
The numbers in context
4 male patients. 3 of 4 cases occurred within the first year of semaglutide treatment. All had significant optic disc edema and intraretinal findings.
How the study worked
Case report series documenting NAION in patients receiving semaglutide, including clinical presentation, temporal association, and outcomes.
Who was studied
4 male patients diagnosed with NAION during semaglutide treatment
What this study cannot tell us
Case reports cannot prove causation. NAION occurs in the general population regardless of medications. Diabetes and obesity are independent NAION risk factors. Publication bias may inflate the apparent association.
How to read the evidence
Preliminary evidence: case reports adding to safety signal data. Causation not established.
When this study was published
Published in 2025. Part of ongoing pharmacovigilance for GLP-1 drug eye safety.
The bigger picture
NAION pharmacovigilance for GLP-1 drugs is ongoing at the FDA and EMA. Each documented case contributes to the evidence base. Eventually, accumulated data will either confirm a causal link or establish that the association is coincidental given the massive user population.
Questions still open
- Will large epidemiological studies confirm or refute the semaglutide-NAION link?
- Are certain GLP-1 drugs associated with higher NAION risk than others?
- Should ophthalmologists ask about GLP-1 drug use when evaluating NAION?
Common questions
Should I worry about my vision on semaglutide?
Has the FDA confirmed semaglutide causes NAION?
Read the original research
Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.
BMC ophthalmology, 25(1), 132
Citation
Ahmadi, Hamid; Hamann, Steffen. (2025). Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.. BMC ophthalmology, 25(1), 132. https://doi.org/10.1186/s12886-025-03958-4